Dr Reddy's Laboratories unveils Pregabalin Capsules in the US market
30 July 2019 -

Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Tuesday announced the availability of Pregabalin Capsules a therapeutic equivalent generic version of Lyrica (pregabalin) Capsules).

According to the company, the Pregabalin Capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg capsules in bottle count sizes of 90. This is a controlled substance schedule V product.

The US Food and Drug Administration (USFDA) approved Lyrica is a trademark of CP PHARMACEUTICALS INTERNATIONAL CV.

For the most recent 12 months ending in May 2019, the Lyrica (pregabalin) Capsules brand had US sales of USD5,462m MAT, according to IQVIA Health.